Home Logon FTA Investment Managers Blog Subscribe About Us Contact Us

Search by Ticker, Keyword or CUSIP       
Blog Home
Bob Carey
Chief Market Strategist
X •  LinkedIn

  FDA Drug Approvals Hit All-Time High In 2018
Posted Under: Sectors
Supporting Image for Blog Post

View from the Observation Deck  

  1. The 59 new drugs approved by the FDA in 2018 eclipsed the previous high of 53 in 1996, according to FierceBiotech. 
  2. One of the catalysts behind the jump in approvals the past two years is a more efficient process. Pharma Exec reported that it took 250 days, on average, for a drug using Fast Track status to be approved by the FDA in 2017, down from 300 days in 2015, and the average days for approval in other expedited categories have also decreased, according to StreetAuthority.
  3. The new drug pipeline is deep. In 2018, there were 7,201 Investigational New Drug (IND) applications on the FDA's books, up 25% from a decade ago, according to FierceBiotech. An IND is a request for authorization from the FDA to administer an investigational drug or biological product to humans.
  4. The FDA plans to hire at least 50 new clinical reviewers to assess cell and gene therapies to prepare for a surge in cutting-edge products, according to FierceBiotech. 
  5. The need for new products is a primary driver of mergers and acquisitions (M&A) in the biotechnology space, particularly for pharmaceutical companies, according to FierceBiotech. In 2017 alone, more than $26 billion in annual sales was vulnerable due to patent expirations, according to StreetAuthority. 
  6. A couple of decades ago, less than 10% of the products in the pharmaceutical pipeline came from biotechnology companies, compared to 65% today, according to Labiotech, a leading digital media firm tracking the European Biotechnology industry. In 2018, 60% of the drugs approved by the FDA came from biotechnology companies.
This chart is for illustrative purposes only and not indicative of any actual investment. 

Download a PDF of this post, please click here.
Posted on Tuesday, January 22, 2019 @ 12:15 PM • Post Link Print this post Printer Friendly

These posts were prepared by First Trust Advisors L.P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.
Search Posts
Market Commentary and Analysis
Market Commentary Video
Monthly Talking Points
Quarterly Newsletter
Market Observations
Subscribe To Receive Email

A Snapshot of Growth vs. Value Investing
S&P 500 Index Earnings & Revenue Growth Rate Projections
Corporate Earnings Are Expected To Increase In 2019
A Snapshot Of How Stocks Have Performed So Far In This Millennium
2019 Market Outlook
A Snapshot of Bond Valuations
Stock Buybacks by Sector
Call Us Crazy ... Stocks on sale as we head into 2019
Sector Performance Via Market Capitalization (Since Steel/Aluminum Tariffs Enacted)
Top-Performing Subsectors in the S&P 500 Index
Skip Navigation Links.
Search by Topic
Skip Navigation Links.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
Follow First Trust:  
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2024 All rights reserved.